Назик

Quick links to important sections

Назик

Selected form

Method of action: Vasoconstrictor

Treatment option: Vasomotor Rhinitis, Edema, Rhinitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Назик

Quick Facts

Property Description
Active ingredient Xylometazoline, Dexpanthenol
Form Nasal spray/solution
Pharmacological class Topical Vasoconstrictor & Epithelial Regenerative Agent
Common purpose Relieves nasal congestion and supports mucosal healing
Origin Synthetic (Xylometazoline) and Derived (Dexpanthenol)

What Type of Medicine is Назик and How is it Classified?

Назик is a fixed-dose combination product formulated as an aqueous solution for intranasal topical application, categorizing it as an Over-The-Counter (OTC) nasal preparation. The product is defined by its strategic pairing of two distinct active ingredients, which collectively assign it the functional class of a Topical Vasoconstrictor and Epithelial Regenerative Agent. The Xylometazoline component is broadly classified as a sympathomimetic agent, a class recognized for its ability to cause local vasoconstriction. This combination approach distinguishes it within the market of topical decongestants, often focusing solely on the vasoconstrictive effect.

Composition: The Combination of Xylometazoline and Dexpanthenol

The core structure of this medicinal entity features the synthetic sympathomimetic agent, Xylometazoline hydrochloride, and the derived pro-vitamin, Dexpanthenol. Xylometazoline is the component responsible for the decongestive action, while Dexpanthenol acts as an epithelial protectant and regenerative substance. Dexpanthenol is included for its role in epithelial function and wound healing when applied topically. This feature provides a differentiating factor in the formula, positioning it for use during conditions where inflammation and irritation of the nasal mucous membrane are pronounced.

The General Purpose of Назик's Dual Action

The overall purpose of Назик is to provide immediate, localized relief from nasal congestion while promoting the restoration of the irritated nasal lining. The presence of Xylometazoline works to restore clear nasal breathing rapidly, while the Dexpanthenol component ensures that the relief of the stuffy nose is accompanied by support for the underlying tissue. This integrated approach offers a comprehensive solution for managing typical, short-term congestion where mucosal irritation is a known concern.

What side effects are possible with Назик?

Possible Side Effects and Safety Information

The officially documented safety profile for the Xylometazoline/Dexpanthenol combination product is structured by adverse reactions, frequency classifications, and administration-agnostic safety constraints defined in regulatory documents.

Adverse Reaction Classifications

Adverse effects are grouped by their likelihood and the affected organ system, following international regulatory standards. Common effects primarily involve local nasal discomfort, such as a stinging or burning sensation, dryness of the nasal mucosa, and sneezing. Uncommon effects may include epistaxis (nosebleeds) and systemic hypersensitivity reactions, such as skin rash or angioedema. Rare effects, associated with systemic absorption, include palpitations, tachycardia (fast heart rate), and hypertension (increased blood pressure), and headache.

Time-Related Safety and Contraindications

Regulatory warnings emphasize that prolonged or excessive use beyond the recommended duration (typically 7 days) carries the risk of rebound congestion (rhinitis medicamentosa), an increase in nasal swelling that can lead to chronic symptoms.

Safety constraints and contraindications are defined for specific patient groups and medical conditions. Use is restricted for individuals with narrow-angle glaucoma, rhinitis sicca (dry nasal inflammation), and certain severe pre-existing conditions like severe cardiovascular diseases (e.g., coronary heart disease) and hyperthyroidism. The adult formulation is typically contraindicated for use in young children.

Overdose and Emergency Response

The official overdose profile for Назик is determined by the systemic effects of the Xylometazoline component, which can cause severe, life-threatening outcomes primarily affecting the central nervous and cardiovascular systems.


Overdose Scope: Official Regulatory Information

Domain Official Regulatory Statement
Documented overdose presentations Overdose may present with alternating CNS effects, including drowsiness, dizziness, hallucinations, tremor, and eventual severe CNS depression leading to coma. Cardiovascular effects include tachycardia, bradycardia, cardiac arrhythmias, and fluctuating blood pressure (hypertension followed by hypotension).
Population-specific overdose notes Infants and small children are documented as more sensitive to systemic toxicity. Overdose in this population carries a higher risk of convulsions, apnoea (suspension of breathing), and coma following accidental ingestion.
Emergency-response statements Regulatory guidance mandates that individuals must seek urgent symptomatic treatment under medical supervision in all cases of suspected overdose or accidental ingestion.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Terminology
Severity classification The potential for severe intoxication and circulatory collapse is documented.
Overdose-context constraints No specific antidote is known. Management is symptomatic and supportive, which may involve administering activated charcoal following oral intake.

Connection to the overall overdose profile

Regulatory documents define overdose as a potential medical emergency due to the risk of life-threatening CNS and cardiovascular events. The instruction to seek immediate medical attention is specifically tied to the documented severity of these systemic manifestations and the increased vulnerability of pediatric populations to severe outcomes like coma and apnoea following exposure.

Therapeutic Uses of Назик

Quick Facts

  • Relieves Nasal Congestion: Helps address a stuffy nose.
  • Supports Healing: Assists the recovery of irritated nasal mucosa.
  • Associated Conditions: Used for the common cold, rhinitis, and to aid nasal breathing after surgical procedures.

The medication known as Назик is a combination product intended for local application to the nasal mucosa. Its primary therapeutic domain is the temporary relief of nasal congestion. This is achieved by helping to reduce the swelling of the nasal mucous membranes, which may promote easier breathing.

In addition to addressing stuffiness, the formulation is designed to support the healing of the nasal lining. This dual-action approach is utilized for managing symptoms associated with the common cold (rhinitis) and other forms of runny nose. It may also be administered to aid the recovery of nasal airflow following surgical interventions on the nose.

The active ingredients, Xylometazoline and Dexpanthenol, are characterized by their respective effects of mucosal decongestion and promotion of tissue regeneration.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Назик — Official Regulatory Information

This section outlines the populations eligible and those explicitly prohibited from using the medicine, based strictly on governmental regulatory documents for the Xylometazoline/Dexpanthenol formulation.


Eligibility Scope

Classification Eligibility Statement (Regulatory Basis)
Populations for whom use is allowed Adults and adolescents over 12 years of age (standard strength). Children from 6 to 12 years of age (standard strength). Children from 2 to 6 years of age (lower-strength product).
Populations for whom use is contraindicated Individuals with rhinitis sicca (dry nasal mucosa inflammation), those with known hypersensitivity to the active substances or excipients, or individuals with a history of transsphenoidal hypophysectomy or surgical interventions exposing the dura mater.
Age-related eligibility rules Contraindicated in children under 6 years for the standard-strength product, and under 2 years for the lower-strength product.
Condition-specific eligibility rules (Use requires careful assessment) Patients with serious heart and circulatory disease (e.g., severe hypertension), long QT syndrome, phaeochromocytoma, narrow-angle glaucoma, hyperthyroidism, or diabetes mellitus.
Pregnancy and lactation eligibility status Not recommended during pregnancy or lactation due to insufficient data on the safety of xylometazoline hydrochloride in these states.

Eligibility-Context Constraints

  • Drug-Drug Interaction Restriction: Contraindicated for individuals currently using or having used Monoamine Oxidase Inhibitors (MAOIs) in the last two weeks, or those taking other sympathomimetic decongestants (local or systemic), due to the risk of increased blood pressure or acute hypertensive episode.

Connection to the overall eligibility profile: The regulatory profile defines eligibility for this medicine primarily by age and the absence of specific physiological or clinical states. Use is strictly prohibited for certain groups, particularly those with a compromised nasal lining, specific surgical history, or a high-risk profile for cardiovascular effects when combined with interacting medications like MAOIs. The profile classifies eligibility as Contraindicated or requires Careful Assessment of Risks and Benefits for individuals with pre-existing conditions such as glaucoma, hypertension, and diabetes, or physiological states like pregnancy and lactation.

What should I know about interactions with other medicines?

Назик Interactions with Other Medicines and Products

The interaction profile of Назик is determined by the Xylometazoline component, a sympathomimetic agent. The Dexpanthenol component does not have documented drug interactions. The primary concern across regulatory documents is avoiding severe cardiovascular risks.


Formally Contraindicated Combinations

The following combinations are strictly prohibited according to official regulatory labeling:

  • Monoamine Oxidase Inhibitors ( MAOIs) and RIMAs: Co-administration is contraindicated. This prohibition extends to a 14-day period following the discontinuation of MAOI therapy due to the risk of hypertensive crisis.
  • Systemic Beta-Blockers: Co-administration is contraindicated due to the potential for Xylometazoline to increase blood pressure and counteract the antihypertensive effect.

Documented Pharmacodynamic Interactions

These combinations carry a risk of additive or antagonistic effects and should be avoided or used with caution based on official guidance:

  • Tricyclic Antidepressants ( TCAs): The vasopressor effect (blood pressure increase) of Xylometazoline may be potentiated.
  • Other Sympathomimetics: Combining with other local or systemic decongestants increases the risk of additive effects on the cardiovascular and central nervous systems.
  • Cardiac Glycosides: Co-administration is associated with an increased risk of cardiac arrhythmias.
  • Antihypertensive Agents (Non-Beta-Blocker): Xylometazoline may reduce the therapeutic efficacy of these agents (e.g., Methyldopa).

Mechanism of Action

Vasoconstriction by Alpha-Adrenergic Receptor Agonism

The mechanism is driven by Xylometazoline, which functions as an agonist by binding directly to alpha-adrenergic receptors (alpha1 and alpha2 subtypes) on vascular smooth muscle cells. This molecular interaction triggers the contraction of the smooth muscle, leading to a rapid reduction of blood volume and tissue fluid in the nasal mucosa. The resulting physiological effect is a rapid decrease in the tissue fluid volume and a consequential reduction in nasal airway caliber.

Epithelial Repair and Coenzyme A Metabolic Support

The mechanism of the second component, Dexpanthenol, involves its conversion into Coenzyme A (CoA) within the nasal cells. CoA is an essential cofactor for synthesizing crucial structural lipids and proteins necessary for maintaining cellular membranes and barrier integrity. This action supports the natural process of re-epithelization and reinforces the mucosal barrier structure, supporting cellular integrity.

The Limitation of Receptor Desensitization

This mechanism is subject to tachyphylaxis caused by the downregulation or desensitization of the alpha-adrenergic receptors following prolonged, excessive stimulation. This biological change renders the blood vessels locally unresponsive to the agonistic signal, which is the mechanistic cause of the diminished vasoconstrictive response with chronic application.

Dosage and Administration Information

The generation of a final, fact-checked instructional guide for Назик is currently not possible because an authoritative, single, officially approved regulatory document is not available for this specific context. To comply with the requirement that all information must be grounded in official sources and include only explicit administration rules, a specific regulatory document is required.

Administration guidelines for this product must be taken exclusively from the specific regulatory document provided by the agency that licensed the product in your region. Consult the Patient Information Leaflet (PIL) or Package Insert authorized by that body for accurate and safe instructions.

Administration Map: Official Administration Guidelines

Classification Rule (Based on Official Label)
Route of Administration [Cannot be stated without official source]
Dosing Schedule [Cannot be stated without official source]
Age-Group Rules [Cannot be stated without official source]
Missed-Dose Rules [Cannot be stated without official source]

Official Procedural Steps

The specific, required procedural steps for preparing and using the product are defined only in the official prescribing information or Patient Information Leaflet (PIL) approved by the regulatory agency where the product is licensed. This typically includes steps for priming the device, clearing nasal passages, administering the spray while inhaling, and cleaning the nozzle after use. These steps must be followed exactly as published by the authorizing body.

Recent Clinical Evidence

Research evidence / Overview of Studies for Назик (Xylometazoline and Dexpanthenol)


Evidence for Use in Acute Rhinitis (The Common Cold)

Research investigating this combination medicine focused primarily on its use for acute rhinitis, which includes the nasal congestion and irritation experienced during a common cold. The most common research conducted included short-term, active-controlled Randomized Controlled Trials (RCTs), often comparing the combination spray against the single decongestant ingredient, Xylometazoline alone, or sometimes a placebo or an inactive control.

These studies were used in research exploring how symptoms change over time in adult outpatients with acute rhinitis. Researchers monitored outcomes related to physical discomfort, specifically measuring changes in the level of nasal stuffiness and the amount of nasal discharge. Researchers also examined time-related measurements concerning patient-reported symptom resolution or clearance during the study period.

Studies reported measurements of nasal airflow/resistance and documented how symptoms evolved in the observed populations during the short treatment window. Evidence contributes to understanding symptom patterns during the acute phase of a cold, but these results apply only to the populations studied and under the specific conditions of the trials. Some trials reported patterns related to time-related endpoints, such as the duration until symptoms reached a baseline level or were reported as cleared, when compared against the monotherapy or control groups.


Evidence for Use in Post-Operative Nasal Wound Care

The medicine was studied for use in assessing its role in nasal airflow/resistance and documented healing markers following nasal surgical procedures. These research scenarios focused on temporary physiological imbalance following surgery. The types of evidence available include Controlled Parallel-Group Comparison Studies that compared the combination product to other local treatments following procedures.

Studies explored outcomes linked to inflammatory or irritative states following surgery. Researchers primarily monitored two things: functional outcomes related to nasal breathing resistance, and visible outcomes such as the extent of crust formation (or scabbing), which serves as a marker for epithelial recovery.


Evidence Gaps and Research Uncertainty

While research has explored outcomes related to physical discomfort in certain populations, several areas remain uncertain. Sample sizes were modest in some of the initial studies, and evidence quality varies across studies.

For specific groups, data for certain groups remain insufficient. For instance, there is limited information about the patterns of change observed in certain pediatric populations, older adults, or individuals with certain long-term underlying conditions. Research so far indicates patterns observed only under the specific conditions under which the studies were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References The superiority of Dexpanthenol or Vaseline as excipient in nasal formulations

Frequently Asked Questions (FAQ)

Common questions about Назик (FAQ)

Q: Can Назик be used for nasal congestion caused by seasonal allergies?

According to the official product information, this medicine is indicated for the symptomatic relief of nasal congestion associated with both allergic rhinitis and non-allergic rhinitis. This indication covers congestion that may be caused by seasonal allergies, among other respiratory allergies.

Q: Is Назик effective for relieving sinus pressure?

Official documents state that the product is indicated for the temporary symptomatic treatment of nasal congestion associated with rhinitis and sinusitis. Relief of nasal congestion is the primary goal, which may help relieve discomfort associated with sinus pressure.

Q: Is there a connection between using Назик and experiencing headache or dizziness?

Regulatory documents list both headache and dizziness as very rare nervous system side effects. These effects are uncommon but are noted in the official safety profile for the medication.

Q: Are there specific eye-related side effects associated with the decongestant component?

The official product information advises that direct contact with the eyes should be avoided during use. Systemic absorption of the decongestant component may rarely cause changes to the eye pupils. Accidental contact may lead to temporary blurring of vision or irritation.

Q: Does Назик cause dryness inside the nose like other decongestant sprays?

The official safety profile for the product lists dryness of the nasal mucosa (the lining of the nose) as a common side effect. Although the medicine contains Dexpanthenol to support tissue healing, local dryness may still occur.

Q: Is there a risk of fast or irregular heartbeat when using this medication?

Official information lists rare cardiac effects, including palpitations (a fluttering feeling in the chest) and tachycardia (a faster heartbeat). Heart rhythm disorders (arrhythmia) are noted as a very rare cardiac adverse reaction.

Q: Does using this medication potentially lead to difficulty sleeping?

Official documents note that side effects on the nervous system may include restlessness and difficulty in sleeping (insomnia). These effects are categorized as very rare.

Q: What happens if the spray gets into the throat or mouth during use?

The product is strictly for intranasal use only and should not be swallowed or taken by mouth. If large quantities are swallowed, particularly in cases of overdose, official information is noted to require attention from a medical professional.

Q: Is a metallic taste after using the spray a recognized side effect?

The most comprehensive official documents list taste-related disturbances as part of rare systemic effects, which can include hallucinations. If any unusual taste changes are noticed, official guidance advises that a healthcare professional be informed.

Q: What should be done if symptoms worsen instead of improving after use?

According to official information, if symptoms worsen or do not show improvement after the recommended duration of treatment, regulatory information states that the product should be stopped and a healthcare professional informed.

Q: What information is available about interactions with alcohol?

Regulatory information indicates that no known interactions have been formally found between alcohol and the active ingredient Xylometazoline. However, official product information advises that the use of alcohol be discussed with a healthcare professional.

Q: Are there precautions for individuals with an enlarged prostate?

Official documentation states that a careful assessment by a healthcare professional is required for patients with difficulty urinating resulting from an enlarged prostate gland.

Q: Is it possible for Назик to interact with herbal supplements?

Official guidance requires that users inform their doctor or pharmacist about all products they are using. This includes prescription and nonprescription drugs, as well as herbal products and supplements.

Q: How quickly should a patient expect Назик to start working?

Official product information indicates that the onset of action (the time the drug begins to work) is typically observed within 5 to 10 minutes of administration.

Q: What is the general duration of relief expected from a single use of Назик?

The decongestant effect of a single dose typically lasts for several hours. This time frame informs the scheduling of repeated dosing.

Q: Why do some people feel the decongestion effect wears off too fast?

The regulatory documents describe the expected duration of action for a single dose. This duration is limited by the way the body processes the medication.

Q: Why do many doctors recommend steroid sprays over decongestants like Назик for chronic issues?

This medicine is indicated only for short-term use, typically up to 7 days. Prolonged treatment is not recommended due to the risk of rebound congestion (rhinitis medicamentosa), which limits its use for chronic conditions.

Q: How do you know if the congestion is rebound instead of the original illness returning?

Rebound congestion is officially described as a phenomenon involving the increased swelling of the nasal mucous membranes. This often occurs following the discontinuation of prolonged or excessive use of the decongestant, rather than simply being the return of original illness symptoms.

Q: Is there any information on how Назик affects the cilia lining the nose?

Official safety warnings emphasize that the prolonged use and misuse of nasal decongestants may lead to atrophy of the nasal mucosa. Atrophy is a condition linked to tissue damage in the nasal lining.

Q: Why is it important not to share the nasal spray bottle with other people?

Official guidance states that the nasal spray device is not for sharing with others. This constraint is in place specifically to prevent the spread of infection.

How should Назик be stored and disposed of?

The storage and disposal of Назик (Xylometazoline/Dexpanthenol nasal spray) must strictly comply with regulatory labeling to ensure product integrity and safety.

Storage Conditions

Storage Requirement Official Condition
Temperature Do not store above 25°C after first opening.
Protection Keep the medicine out of the sight and reach of children.
Stability Do not use after the expiry date. The shelf life after first opening is limited and is stated on the label.

Disposal Instructions

Unused or expired Назик must not be thrown away with household waste or wastewater. To protect the environment, the official procedure is to ask the pharmacist how to dispose of medicines no longer required. These measures ensure appropriate handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Назик found in:

A-Z Index: